• vTv Therapeutics completed enrollment in its Phase 3 CATT1 trial of cadisegliatin as an adjunct to insulin in type 1 diabetes.
• Topline results have not been presented yet; reporting is targeted for mid-2027.
• The study is designed to show whether cadisegliatin can lower clinically significant hypoglycemia while improving overall glucose control.
• Cadisegliatin is an oral, liver-selective glucokinase activator with FDA Breakthrough Therapy designation for adjunctive treatment in type 1 diabetes.
• Enrollment reached 166 randomized patients, positioning the program for a key readout that could shape the regulatory path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839228) on October 05, 2026, and is solely responsible for the information contained therein.